Nektar Therapeutics Initiates First Two Global Registrational Trials, ZENITH AD-1 and ZENITH AD-2, In Its Phase 3 Program For Rezpegaldesleukin; Initial Phase 3 Topline Data Expected In Mid-2028 With BLA Submission Targeted For 2029

Two global registrational Phase 3 trials initiated in ZENITH AD program

Phase 3 program based upon clinically meaningful efficacy and favorable safety data observed in 393-patient Phase 2b study with monthly and quarterly maintenance dosing, including an up to five-fold increase in EASI-100 between 16 and 52 weeks

ZENITH AD program includes these first two 510-patient studies in patients who are systemic biologic/JAK inhibitor treatment-naive (ZENITH AD-1 and ZENITH AD-2) and one 510-patient study in patients who are treatment-experienced (ZENITH AD-3), which will begin in September